%0 Journal Article %J J Alzheimers Dis %D 2016 %T Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease. %A Pierrot, Nathalie %A Lhommel, Renaud %A Quenon, Lisa %A Hanseeuw, Bernard %A Dricot, Laurence %A Sindic, Christian %A Maloteaux, Jean-Marie %A Octavea, Jean-Noël %A Ivanoiu, Adrian %K Aged %K Alzheimer Disease %K Amyloidogenic Proteins %K Biomarkers %K Cognition Disorders %K Humans %K Male %K Mental Recall %K Neuropsychological Tests %K Receptors, Retinoic Acid %K tau Proteins %K Tetrahydronaphthalenes %X

We present the effects of Targretin® (bexarotene) on cognition and biomarkers in a patient with mild Alzheimer's disease (AD). Targretin® is a Retinoic X Receptor (RXR) agonist shown to improve synaptic and cognitive functions in animal models of AD by increasing neuronal cholesterol efflux. After 6 months of treatment with Targretin® 300 mg/day, memory improved by about 40% and the tau protein in the cerebrospinal fluid decreased by about 20% . No significant side effects were noticed. This observation in a single patient indicates that Targretin® may improve memory performance and biological markers at an early stage of AD.

%B J Alzheimers Dis %V 49 %P 271-6 %8 2016 %G eng %N 2 %1 http://www.ncbi.nlm.nih.gov/pubmed/26444777?dopt=Abstract %R 10.3233/JAD-150405